How to Get Zetia (Ezetimibe) in Minnesota

What Is Ezetimibe and Why Minnesota Clinicians Prescribe It

Ezetimibe 10 mg once daily lowers LDL cholesterol by 18-25% by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing dietary and biliary cholesterol absorption. It is approved by the FDA as an adjunct to diet and, when appropriate, to statin therapy for primary hyperlipidemia, mixed hyperlipidemia, and homozygous familial hypercholesterolemia. The FDA label for ezetimibe is publicly available through the FDA's drug database.

The drug's cardiovascular credentials come primarily from the IMPROVE-IT trial, published in the New England Journal of Medicine in 2015. That randomized controlled trial enrolled 18,144 patients with recent acute coronary syndrome and randomized them to simvastatin 40 mg alone or simvastatin 40 mg plus ezetimibe 10 mg. At a median follow-up of 6 years, the combination group achieved a mean LDL-C of 53.7 mg/dL versus 69.5 mg/dL in the monotherapy group. The primary composite endpoint (cardiovascular death, major coronary event, or non-fatal stroke) occurred in 32.7% of the combination group versus 34.7% of the simvastatin-alone group, an absolute risk reduction of 2.0 percentage points and a relative risk reduction of 6.4% (P<0.001). [1]

The 2022 ACC/AHA Guideline on the Management of Blood Cholesterol states: "In patients with clinical ASCVD on maximally tolerated statin therapy who remain above LDL-C thresholds, ezetimibe is recommended as a first nonstatin add-on." [2] That guidance directly informs what Minnesota prescribers look for before writing the script.

Minnesota has roughly 5.7 million residents as of 2024 [3], and the state's telehealth parity law means any licensed Minnesota clinician can assess, diagnose, and prescribe through synchronous audio-video without a prior in-person visit for most conditions, including hyperlipidemia. [4]

Who Can Prescribe Zetia in Minnesota

Any licensed prescriber with Minnesota DEA and state licensure authority can write an ezetimibe prescription. Ezetimibe is not a controlled substance, so the prescribing rules are simpler than for Schedule II-IV drugs. Minnesota statute grants prescriptive authority to MDs, DOs, NPs (under collaborative practice or independent practice depending on licensure tier), and PAs. [4]

Specifically, Minnesota Statute 148.235 allows advanced practice registered nurses to prescribe independently after 2 to 080 hours of supervised practice without ongoing physician collaboration. That means a telehealth NP practicing exclusively in Minnesota can assess your lipid panel and write for ezetimibe without a supervising physician co-signing. PAs in Minnesota operate under a delegation agreement with a collaborating physician, but that agreement is internal to the practice and does not require you, the patient, to interact with the physician directly.

In practice, you will encounter three types of prescribers in Minnesota telehealth encounters for ezetimibe:

Cardiologists and internal medicine physicians, who tend to manage patients with established ASCVD or familial hypercholesterolemia. Primary care physicians and family medicine doctors, the most common prescribers for de novo hyperlipidemia. Nurse practitioners and PAs working within telehealth platforms, who handle straightforward cases where labs already exist or can be ordered through the platform.

All three can legally and clinically initiate ezetimibe in Minnesota today. The deciding factor is usually which route gets you seen fastest.

What Labs Are Required Before Starting Zetia in Minnesota

Before any clinician writes for ezetimibe, they need a fasting lipid panel. No exceptions exist in published guidelines. The ACC/AHA recommends a fasting lipid panel (8-12 hour fast) to establish baseline LDL-C, total cholesterol, HDL-C, and triglycerides before initiating any lipid-lowering therapy. [2] Most Minnesota telehealth platforms either accept a lipid panel drawn within the past 12 months or send you an order to a local Quest Diagnostics or LabCorp draw site before the prescribing visit.

Beyond the lipid panel, your prescriber may order:

Liver function tests (AST/ALT). Ezetimibe is metabolized via glucuronidation in the small intestine and liver. The FDA label notes that ezetimibe is not recommended in patients with moderate or severe hepatic impairment. [5] If you are also starting or already on a statin, baseline ALT establishes a reference point.

Thyroid-stimulating hormone (TSH). Secondary hypercholesterolemia from hypothyroidism is common and should be excluded before attributing elevated LDL-C to primary dyslipidemia. The American Association of Clinical Endocrinology recommends TSH screening in patients with newly discovered dyslipidemia. [6]

Creatinine/eGFR. Dose adjustments for ezetimibe are not required in renal impairment per the FDA label, but co-prescribed statins may require dose capping, and your prescriber needs a renal baseline. [5]

Fasting glucose or HbA1c. ACC/AHA 2018 guidelines note the association between statin therapy and new-onset diabetes risk, and a glucose baseline contextualizes that risk.

Most patients need only the fasting lipid panel and, if not done recently, a TSH. Turnaround from a major Minnesota lab (LabCorp has 47 patient service centers in Minnesota; Quest operates more than 30) is typically 24-48 hours. [7][8]

How to Get a Zetia Prescription in Minnesota: Step-by-Step

Getting ezetimibe in Minnesota follows a predictable four-step sequence regardless of whether you use an in-person office or telehealth.

Step 1: Confirm your labs exist or get them ordered. If you have a lipid panel from the past 12 months, locate the report from your patient portal or request records. If not, a telehealth platform can order labs in advance or you can visit any Minnesota walk-in lab. H&L Labs, Fairview laboratory services, and both Quest and LabCorp accept self-pay orders without a prior physician order in Minnesota.

Step 2: Schedule a prescribing visit. An in-person visit with a primary care physician in Minnesota averages 18-24 days for a new patient appointment as of 2024, per MGMA wait-time benchmarks. [9] Telehealth visits for established conditions like hyperlipidemia are typically available same-day or next-day through platforms that hold Minnesota licensure. The visit itself runs 15-20 minutes for a straightforward lipid management consultation.

Step 3: Receive the prescription. Ezetimibe is transmitted electronically to your preferred pharmacy through Minnesota's e-prescribing infrastructure. Minnesota has mandated electronic prescribing for most medications since 2011. [4] The prescription may go to a retail chain (CVS, Walgreens, or the 130+ independent pharmacies across the Twin Cities metro), a mail-order pharmacy, or a 503A compounding pharmacy if your prescriber writes for a compounded form.

Step 4: Fill and pick up or receive by mail. Same-day pickup is possible at most Minnesota retail pharmacies once the script is transmitted. Mail-order delivery (USPS or UPS) within Minnesota takes 1-3 business days from most platforms that ship from in-state fulfillment hubs.

Telehealth Prescribing of Zetia in Minnesota

Minnesota's telehealth parity statute (Minnesota Statutes Section 62A.673) requires that commercial insurers cover telehealth services at parity with in-person services as long as the service is clinically appropriate via that modality. [4] Hyperlipidemia management is explicitly appropriate for audio-video telehealth: no physical examination finding changes the ezetimibe prescribing decision beyond what labs and medical history provide.

The practical steps for a telehealth Zetia encounter in Minnesota are straightforward. You create an account on a licensed telehealth platform, submit your lipid panel and any recent medication list, complete a 15-minute video or phone visit with a Minnesota-licensed NP, PA, or physician, and receive an electronic prescription transmitted to your pharmacy of choice.

The Centers for Medicare and Medicaid Services reported that telehealth utilization in Minnesota increased by more than 4,000% during 2020 and has stabilized at roughly 38 times pre-pandemic baseline volumes for chronic disease management. [10] That infrastructure means same-day prescribing visits are consistently available.

One nuance: a prescriber must have an active Minnesota medical license to prescribe for a patient physically located in Minnesota. Confirm the platform you choose lists Minnesota as a covered state before booking. Platforms operating under the Interstate Medical Licensure Compact include many states but not all platforms carry Minnesota licensure for every clinician on their roster.

Ezetimibe Cost and Insurance Coverage in Minnesota

Generic ezetimibe 10 mg is available at most Minnesota retail pharmacies. The GoodRx cash price for a 30-day supply of generic ezetimibe at Minnesota pharmacies (Minneapolis/St. Paul metro) runs approximately $15-29 depending on the specific pharmacy and coupon applied. [11] That price applies without insurance.

Minnesota Medicaid (Medical Assistance) covers ezetimibe with prior authorization (PA) for members with a documented diagnosis of hyperlipidemia or mixed dyslipidemia when diet and statin therapy are documented as inadequate or contraindicated. The Minnesota Department of Human Services Preferred Drug List classifies ezetimibe as non-preferred on the PDL, which triggers the PA requirement. [12]

For commercial insurance in Minnesota, most formularies place generic ezetimibe on Tier 1 or Tier 2, with typical copays of $0-25 per month. The brand-name Zetia (Merck) runs substantially higher on most formularies; your prescriber can request a step-edit waiver or simply prescribe the generic, which is therapeutically identical.

Medicare Part D plans in Minnesota vary: in 2024, generic ezetimibe appeared on Tier 2 in most Minnesota Part D formularies, with a standard copay of $0-$10 under the Inflation Reduction Act drug price negotiation provisions that took effect for some plans. [13]

Prior Authorization for Zetia in Minnesota Medicaid

Minnesota Medicaid PA for ezetimibe typically requires:

A documented LDL-C above the patient's risk-stratified threshold (for example, LDL-C above 70 mg/dL in patients with clinical ASCVD, per ACC/AHA 2018 guidelines). [2] Documentation that the patient has tried and failed, or has a contraindication to, at least one statin. A prescriber attestation that ezetimibe is being added as an adjunct to maximally tolerated statin therapy or as monotherapy where statins are contraindicated. The PA form from the Minnesota DHS, completed by the prescribing clinician or their clinical staff.

Turnaround for Minnesota Medicaid PA decisions is 72 hours for standard requests and 24 hours for urgent requests under Minnesota Statute 256B.0625. [12] If PA is denied, your prescriber can file a clinical appeal citing the ACC/AHA guideline language and IMPROVE-IT data.

503A Compounding Pharmacies and Ezetimibe in Minnesota

Licensed 503A compounding pharmacies in Minnesota can compound ezetimibe for individual patients when a prescriber writes a prescription with documented clinical rationale. Common reasons include swallowing difficulty requiring a liquid suspension, or allergy to tablet excipients. The Minnesota Board of Pharmacy licenses 503A facilities under state law aligned with federal USP 795 and 797 standards. [14]

503A compounded ezetimibe is not FDA-approved, and the compounded product does not carry the same bioavailability data as the commercially manufactured tablet. The FDA has not designated ezetimibe as a drug on the shortage list, so compounding under 503A requires a specific patient need documented in the prescription rather than shortage justification. [5]

If your prescriber writes for compounded ezetimibe, confirm the 503A pharmacy holds an active Minnesota Board of Pharmacy license. You can verify licensure at the Minnesota e-licensing portal without charge.

Transferring a Zetia Prescription to Minnesota

If you are moving to Minnesota or have an existing ezetimibe prescription from another state, Minnesota pharmacy law permits transfer of non-controlled prescriptions between licensed pharmacies. Minnesota Statute 151.37 allows a pharmacist to accept a transfer from an out-of-state pharmacy for prescriptions with remaining refills. [15] Because ezetimibe is not a controlled substance, the transfer is straightforward.

Steps: Call your current pharmacy and ask them to transfer the remaining refills to a Minnesota-licensed pharmacy. Provide the name, address, and phone number of your chosen Minnesota pharmacy. Confirm the transfer is complete before the prescription expires. Most pharmacies complete transfers within 2-4 hours.

If your out-of-state prescription has no refills remaining, a Minnesota-licensed prescriber will need to issue a new prescription. A telehealth visit using your existing lipid panel and prescription history is typically sufficient for a new clinician to issue continuity-of-care prescribing on the same day.

Drug Interactions and Clinical Monitoring After Starting Zetia

Ezetimibe carries a low systemic drug interaction burden because its primary metabolism is intestinal glucuronidation rather than hepatic CYP450 enzymes. The FDA label identifies two interactions worth knowing. [5]

Cyclosporine increases ezetimibe AUC by approximately 3.4-fold. Patients on cyclosporine (common in renal transplant recipients) should use ezetimibe with caution and at reduced monitoring intervals. Bile acid sequestrants (cholestyramine, colesevelam) reduce ezetimibe absorption; the FDA label recommends separating doses by at least 2 hours before or 4 hours after the bile acid sequestrant.

Fibrates other than fenofibrate may increase cholesterol excretion into bile and, in combination with ezetimibe, increase the risk of cholelithiasis. Gemfibrozil is not recommended in combination with ezetimibe per the FDA label. [5]

After starting ezetimibe, most Minnesota clinicians follow up with a repeat fasting lipid panel at 6-8 weeks to assess LDL-C response. A 2014 meta-analysis in the Journal of the American College of Cardiology (N=27,564 patients across 26 trials) confirmed that ezetimibe produces a mean LDL-C reduction of 23.7% from baseline when added to statin therapy. [16] If your LDL-C has not moved adequately at 8 weeks, your prescriber may reassess adherence, dietary contributors, or whether a PCSK9 inhibitor should be added.

A repeat hepatic function panel is not routinely required after starting ezetimibe in the absence of symptoms unless the patient is also on statin therapy, in which case statin monitoring guidelines apply. The ACC/AHA 2018 guideline states that routine CK or hepatic monitoring is not recommended for ezetimibe monotherapy. [2]

Ezetimibe 10 mg once daily. No titration required. Take at any time of day, with or without food.